How do angiopoietins Tie in with vascular endothelial growth factors?

Current Opinion in Hematology

Volumn 17, Issue 3, 2010, Pages 198-205

  Saharinen, Pipsa ^a   Bry, Maija ^a   Alitalo, Kari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiogenesis; Angiopoietin; Lymphangiogenesis; Tie2; Vascular endothelial growth factor; Vascular endothelial growth factor B

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; TIE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; CELL JUNCTION; ENDOTHELIUM CELL; ENERGY METABOLISM; HEART MUSCLE METABOLISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANGIOPOIETINS; ANIMALS; HUMANS; LYMPHATIC VESSELS; RECEPTORS, TIE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77951499651     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283386673     Document Type: Review

References (95)

1. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10:165-177.
2. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009; 29:789-791.
3. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21:154-165.
4. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 367:70-74.
5. Puri MC, Rossant J, Alitalo K, et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 1995; 14:5884-5891.
6. Suri C, Jones PF, Patan S, et al. Requisite roleof angiopoietin-1, aligandforthe TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171-1180.
7. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60.
8. Kim I, Kim JH, Moon SO, et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 2000; 19:4549-4552.
9. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001; 49:659-670.
10. Daly C, Pasnikowski E, Burova E, et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci USA 2006; 103:15491-15496.
11. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994-1998.
12. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008; 3:367-397.
13. Karkkainen MJ, HaikoP, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5:74-80.
14. Baldwin ME, Halford MM, Roufail S, et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol 2005; 25:2441-2449.
15. Haiko P, Makinen T, Keskitalo S, et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol 2008; 28:4843-4850.
16. Koch M, Dettori D, Van Nuffelen A, et al. VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J Pathol 2009; 219:356-364.
17. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3:411-423.
18. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
19. Loges S, Roncal C, Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost 2009; 7:21-33.
20. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8:464-478.
21. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16:196-208.
22. Herbert SP, Huisken J, KimTN, et al. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 2009; 326:294-298.
23. Hogan BM, Herpers R, Witte M, et al. Vegfc/Flt4 signalling is suppressed by Dll4 in developing zebrafish intersegmental arteries. Development 2009; 136:4001-4009.
24. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656-660.
25. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66-70.
26. Kappas NC, Zeng G, Chappell JC, et al. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 2008; 181:847-858.
27. Chappell JC, Taylor SM, Ferrara N, Bautch VL Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 2009; 17:377-386.
28. Dawson MR, Duda DG, Chae SS, et al. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One 2009; 4:e6525.
29. Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 2009; 119:845-856.
30. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for antiangiogenic therapy? Nat Rev Cancer 2008; 8:942-956.
31. Karpanen T, Bry M, Ollila HM, et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res 2008; 103:1018-1026.
32. Zentilin L, PuligaddaU, Lionetti V, et al. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J 2009 [Epub ahead of print].
33. Kim KT, Choi HH, Steinmetz MO, et al. Oligomerization and multimerization is critical for angiopoietin-1 to bind and phosphorylate tie2. J Biol Chem 2005; 280:20126-20131.
34. Davis S, Papadopoulos N, Aldrich TH, et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and super-clustering. Nat Struct Biol 2003; 10:38-44.
35. Kim HZ, Jung K, Kim HM, et al. A designed angiopoietin-2 variant, pentameric COMP-Ang2, strongly activates Tie2 receptor and stimulates angiogenesis. Biochim Biophys Acta 2009; 1793:772-780.
36. Bogdanovic E, Coombs N, Dumont DJ. Oligomerized Tie2 localizes to clathrin-coated pits in response to angiopoietin-1. Histochem Cell Biol 2009; 132:225-237.
37. Wehrle C, Van Slyke P, Dumont DJ. Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required for internalization and degradation. Biochem J 2009; 423:375-380.
38. Winderlich M, Keller L, Cagna G, et al. VE-PTP controls blood vessel development by balancing Tie-2 activity. J Cell Biol 2009; 185:657-671.
39. Wouters V, Limaye N, Uebelhoer M, et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010; 18:414-420.
40. Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009; 41:118-124.
41. Fukuhara S, Sako K, Minami T, et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 2008; 10:513-526.
42. Saharinen P, Eklund L, Miettinen J, et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008; 10:527-537.
43. Wong AL, Haroon ZA, Werner S, et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997; 81:567-574.
44. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150-4156.
45. Jang C, Koh YJ, Lim NK, et al. Angiopoietin-2 exocytosis is stimulated by sphingosine-1-phosphate in human blood and lymphatic endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29:401-407.
46. Veikkola T, Lohela M, Ikenberg K, et al. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J 2003; 17:2006-2013.
47. Shimoda H. Immunohistochemical demonstration of angiopoietin-2 in lymphatic vascular development. Histochem Cell Biol 2009; 131:231-238.
48. Sako K, Fukuhara S, Minami T, et al. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. J Biol Chem 2009; 284:5592-5601.
49. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 2008; 14:25-36.
50. Oubaha M, Gratton JP. Phosphorylation of endothelial nitric oxide synthase by atypical PKCzeta contributes to angiopoietin-1-dependent inhibition of VEGF-induced endothelial permeability in vitro. Blood 2009; 114:3343-3351.
51. Lee SW, Kim WJ, Jun HO, et al. Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. Int J Mol Med 2009; 23:279-284.
52. Fachinger G, Deutsch U, Risau W. Functional interaction of vascular en-dothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene 1999; 18:5948-5953.
53. Nottebaum AF, Cagna G, Winderlich M, et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J Exp Med 2008; 205:2929-2945.
54. Yacyshyn OK, Lai PF, Forse K, et al. Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells. Angiogenesis 2009; 12:25-33.
55. Dominguez MG, Hughes VC, Pan L, et al. Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryoni-cally because of defects in angiogenesis. Proc Natl Acad Sci USA 2007; 104:3243-3248.
56. Baumer S, Keller L, Holtmann A, et al. Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood 2006; 107:4754-4762.
57. Li Z, Huang H, Boland P, et al. Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis. Proc Natl Acad Sci USA 2009; 106:22399-22404.
58. Takakura N, Kidoya H. Maturation of blood vessels by haematopoietic stem cells and progenitor cells: involvement of apelin/APJ and angiopoietin/Tie2 interactions in vessel caliber size regulation. Thromb Haemost 2009; 101:999-1005.
59. Mellberg S, Dimberg A, Bahram F, et al. Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis. FASEB J 2009; 23:1490-1502.
60. Saharinen P, Kerkela K, Ekman N, et al. Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 2005; 169:239-243.
61. Milner CS, Hansen TM, Singh H, Brindle NP. Roles of the receptor tyrosine kinases Tie1 and Tie2 in mediating the effects of angiopoietin-1 on endothelial permeability and apoptosis. Microvasc Res 2009; 77:187-191.
62. Chen-Konak L, Guetta-Shubin Y, Yahav H, et al. Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells. FASEB J 2003; 17:2121-2123.
63. Hansen TM, Singh H, Tahir TA, Brindle NP. Effects of angiopoietins-1 and-2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cell Signal 2010; 22:527-532.
64. Singh H, Milner CS, Aguilar Hernandez MM, et al. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. Cell Signal 2009; 21:1346-1350.
65. D'Amico G, Korhonen E, Waltari M, et al. Loss of Endothelial Tie1 Receptor Impairs Lymphatic Vessel Development. Arterioscler Thromb Vasc Biol 2009; 30:207-209.
66. Shimoda H, Bernas MJ, Witte MH, et al. Abnormal recruitment of perien-dothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res 2007; 328:329-337.
67. Dellinger M, Hunter R, Bernas M, et al. Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol 2008; 319:309-320.
68. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118:149-161.
69. Gomei Y, NakamuraY, Yoshihara H, et al. Functional differences between two Tie2 ligands, angiopoietin-1 and-2, in regulation of adult bone marrow hematopoietic stem cells. Exp Hematol 2009; 38:82-89.
70. Lancrin C, Sroczynska P, Stephenson C, et al. The haemangioblast generates haematopoietic cells through ahaemogenic endothelium stage. Nature 2009;457:892-895.
71. Eilken HM, NishikawaS,SchroederT. Continuous single-cell imaging of blood generation from haemogenic endothelium. Nature 2009; 457:896-900.
72. Chen MJ, Yokomizo T, Zeigler BM, et al. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 2009; 457:887-891.
73. Abou-Khalil R, Le Grand F, Pallafacchina G, et al. Autocrine and paracrine angiopoietin 1/Tie-2 signaling promotes muscle satellite cell self-renewal. Cell Stem Cell 2009; 5:298-309.
74. Arsic N, Zacchigna S, Zentilin L, et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther 2004; 10:844-854.
75. Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009; 69:1324-1333.
76. Szarvas T, Jager T, Totsch M, et al. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 2008; 14:8253-8262.
77. Helfrich I, Edler L, Sucker A, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15:1384-1392.
78. Detjen KM, Rieke S, Deters A, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010; 16:420-429.
79. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-516.
80. Sarraf-Yazdi S, Mi J, Moeller BJ, et al. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res 2008; 146:16-23.
81. Brown JL, Cao ZA, Pinzon-Ortiz M, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010; 9:145-156.
82. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27:3557-3565.
83. Falcon BL, Hashizume H, Koumoutsakos P, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009; 175:2159-2170.
84. Reiss Y, Knedla A, Tal AO, et al. Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J Pathol 2009;217:571-580.
85. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-239.
86. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9:685-693.
87. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553-563.
88. Huang J, Bae JO,Tsai JP, et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol 2009; 34:79-87.
89. Holopainen T, Huang H, Chen C, et al. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Res 2009; 69:4656-4664.
90. Shojaei F, Zhong C, Wu X, et al. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008; 18:372-378.
91. De Palma M, Mazzieri R, Politi LS, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008; 14:299-311.
92. Pucci F, Venneri MA, Biziato D, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114:901-914.
93. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239.
94. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231.
95. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev [Epub ahead of print]